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Infection with Salmonella enterica serotype Typhimurium 
sequence type (ST) 313 is associated with high rates of 
drug resistance, bloodstream infections, and death. To 
determine whether ST313 is dominant in the Democratic 
Republic of the Congo, we studied 180 isolates collected 
during	2007–2011;	96%	belonged	to	CRISPOL	type	CT28,	
which is associated with ST313.
Salmonella enterica serotype Typhimurium multilocus sequence type (ST) 313 has been reported as an emerg-
ing cause of invasive salmonellosis in sub-Saharan Africa 
(1). ST313 is almost exclusively from sub-Saharan Africa, 
is characterized by a degraded genome capacity similar to 
that of S. enterica ser. Typhi, has high rates of antimicro-
bial drug resistance, and is associated with bloodstream 
infections and mortality rates >25% (2). Whole-genome 
sequence analysis of 129 ST313 strains, isolated during 
1988–2010 from 7 countries of sub-Saharan Africa, identi-
fied 2 dominant genetic lineages, I and II. These lineages 
emerged ≈52 and ≈32 years ago, respectively, possibly co-
evolving with the spread of HIV (3). Although lineage I 
has not been observed since the mid-2000s, lineage II has 
been observed with increasing frequency. However, data 
from Central Africa, particularly the Democratic Republic 
of the Congo (DRC) are scarce, and information is limited 
to 10 genomes from strains isolated >20 years ago (3). To 
determine whether ST313 is the dominant ST among inva-
sive Salmonella Typhimurium in the DRC, we studied 180 
isolates collected during 2007–2011.
The Study
We earlier described a series of invasive non-Typhi 
Salmonella isolates from blood cultures collected in 7 of 
the 11 provinces in the DRC during 2007–2011 (Figure 1) 
(4). In that study, a health care facility–based survey was 
administered to persons who met the eligibility criteria 
of suspected bacteremia at time of presentation and pa-
tient age >2 months. Blood culture vials were shipped to 
Kinshasa and processed according to standard identifica-
tion procedures (4). A total of 233 non-Typhi Salmonella 
isolates were recovered, 184 (79%) of which belonged 
to serotype Typhimurium (4). The serotypes for all S. 
enterica ser. Typhimurium isolates were determined locally 
and later confirmed at the Institute of Tropical Medicine, 
Antwerp, Belgium. Most (180/184, 98.7%) S. enterica ser. 
Typhimurium isolates were subsequently shipped to the 
Pasteur Institute, Paris, France, for further analysis.
The population structure of these 180 S. enterica ser. 
Typhimurium isolates was assessed by CRISPOL typing. 
CRISPOL is a recently developed high-throughput assay 
based on clustered regularly interspaced short palindrom-
ic repeat (CRISPR) polymorphisms (5). This bead-based 
hybridization assay is designed to detect the presence or 
absence of 72 short variable DNA sequences (spacers) 
from both CRISPR loci of S. enterica ser. Typhimurium. 
Initially, 245 different CRISPOL types (CTs) were identi-
fied in a 2012 study that included 2,200 isolates (5); just 
before we conducted the study reported here, the CRISPOL 
Salmonella Typhimurium database of the Pasteur Institute 
contained >7,000 strains comprising >750 different CTs.
A total of 174 (96.7%) S. enterica ser. Typhimurium 
isolates from the DRC belonged to the CT28 group, of 
which 163 (90.5%) were CT28. A total of 11 (6.1%) iso-
lates belonged to 7 other CTs that were single-spacer vari-
ants (loss of a single spacer), single-event variants (loss of 
>2 contiguous spacers), or double-event variants of CT28 
(Figure 2). Six (3.3%) isolates belonged to 2 CTs not re-
lated to CT28. CT28 had been associated with ST313 in 
a multidrug-resistant DT56 S. enterica ser. Typhimurium 
isolate from Senegal and in the D23580 ST313 lineage II 
genome (5). In contrast, the analysis of raw pyrosequence 
data for genome A130 (3), representative of ST313 lineage 
I, corresponded to CT698, distinct from the CT28 group.
To confirm the association of ST313 to the CT28 
group, we performed multilocus sequence typing (MLST) 
(6) on 12 isolates. A total of 3 isolates belonged to CT28, 
and 1 isolate of each single-spacer, single-event, and dou-
ble-event variant was tested, resulting in 10 isolates from 
the CT28 group. We also performed MLST on 1 isolate of 
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each of the 2 non–CT28 group isolates. All 10 CT28 group 
isolates tested were ST313; both non–CT28 group isolates 
tested were ST19.
Antimicrobial drug susceptibility has been studied with 
a limited panel of 7 drugs (4). We performed additional sus-
ceptibility testing by disk diffusion with a panel of 32 an-
timicrobial agents (Bio-Rad, Marnes-La-Coquette, France) 
(7). Extended-spectrum β-lactamase (ESBL) phenotype 
was assessed by using the double-disk synergy method 
(8). For all ESBL-producing isolates, MICs of ceftriaxone, 
ceftazidime, azithromycin, and imipenem were determined 
by the Etest macromethod (bioMérieux, Marcy L’Etoile, 
France). Results were interpreted according to break points 
defined by the Antibiogram Committee of the French Soci-
ety for Microbiology (www.sfm-microbiologie.org/). Sus-
ceptible strains were defined as having a ceftriaxone MIC 
<1 mg/L, ceftazidime MIC <4 mg/L, azithromycin MIC 
<16 mg/L, and imipenem MIC <2 mg/L. Resistance was 
defined as having a ceftriaxone MIC >2 mg/L, ceftazidime 
MIC >4 mg/L, azithromycin MIC >16 mg/L, and imipenem 
MIC >8 mg/L. The presence of macrolide resistance genes 
was assessed by PCR and sequencing as described else-
where (7). Of the 174 CT28 group isolates, 167 (96%) were 
resistant to ampicillin, chloramphenicol, and trimethoprim/
sulfamethoxazole in combination with other drugs (Figure 
2); the remaining isolates were resistant to 1 or 2 of these 
drugs. Two isolates were resistant to extended-spectrum 
cephalosporins (ceftriaxone MIC 6–32 mg/L, ceftazidime 
MIC 4–32 mg/L); both contain the ESBL blaSHV-2a gene (4). 
We report that both isolates contain the mph(A) gene en-
coding a macrolide 2′-phosphotransferase that inactivates 
macrolides (azithromycin MIC 96–128 mg/L). All 6 non-
CT28 group isolates were susceptible to all drugs tested 
(Figure 2).
Conclusion
Our data are based on the analysis of S. enterica ser. 
Typhimurium isolates recovered from >9,600 blood cul-
tures collected during a 4-year period from distinct parts 
of the DRC. We found that >96% of the S. enterica ser. 
Typhimurium isolates belonged to the CT28 group. Be-
cause of the strong association between CT28 group and 
ST313, our findings suggest high rates of ST313 among 
invasive salmonellosis in the DRC.
Of the 10 genomes from the DRC isolated during 
1988–1992 (3), genetic lineages I and II were identified 
at approximately equal rates. Of the more recent isolates 
(2007–2011) described here, all ST313 isolates belonged 
to the CT28 group, associated with lineage II. A notable 
feature of lineage II is chloramphenicol resistance resulting 
from a cat gene within a specific Tn21-like element, car-
ried by the virulence-associated plasmid pSLT (3). In the 
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Figure 1. Provinces with sample 
collection sites (circled) in the 
Democratic Republic of the Congo, 
2007–2011 (4).
S. enterica Typhimurium Infections, DRC
set described herein, we observed chloramphenicol resis-
tance in >97% of all isolates belonging to the CT28 group. 
The almost complete replacement of lineage I isolates by 
lineage II isolates from Kenya and Malawi has also been 
reported (1,9).
Our data are based on invasive S. enterica Typhimuri-
um isolates collected in a nonsystematic health care facil-
ity–based approach and do not include noninvasive strains 
of S. enterica Typhimurium. Wain et al. (10) recently 
cited unpublished data showing that ST313 S. enterica 
Typhimurium might be a common cause of gastroenteritis 
among immune-competent patients. A human reservoir for 
multidrug-resistant S. enterica Typhimurium and Enteriti-
dis in Kenya has been suggested because of the presence of 
similar strains in asymptomatic siblings and parents of in-
dex case-patients (carriage prevalence 6.9%) (11). Whole-
genome sequencing of ST313 strains has shown genome 
degradation, including pseudogene formation and chromo-
somal deletions as have been observed for human-restricted 
S. enterica Typhi (12,13), suggesting that ST313 might be 
undergoing an evolution toward niche specialization or, 
more likely, human adaptation (1).
Our results indicate very high rates of multidrug-re-
sistant S. enterica Typhimurium ST313 among invasive 
non-Typhi Salmonella infections in the DRC. Future field 
studies involving patients with uncomplicated Salmonel-
la spp. infections will help determine whether ST313 S. 
enterica Typhimurium in Central Africa is an opportunist or 
a primary pathogen. Systematic analyses of potential non-
human and human reservoirs of S. enterica Typhimurium 
might provide a better understanding of the transmission 
dynamics of this emerging pathogen.
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Figure	 2.	 Representative	 CRISPOL	 profiles	 of	 Salmonella enterica serotype Typhimurium	 isolates	 studied.	 CRISPOL	 is	 a	 recently	
developed high-throughput assay based on clustered regularly interspaced short palindromic repeats (CRISPR) polymorphisms. Black 
squares indicate presence of the CRISPR spacer, detected by the corresponding probe; white squares indicates absence of the spacer. 
The	dendrogram	was	generated	by	using	BioNumerics	version	6.6	software	(Applied	Maths,	Sint-Martens-Latem,	Belgium)	as	described	
(5).	The	CRISPOL	types	(CTs)	detected	among	the	180	isolates	from	the	Democratic	Republic	of	Congo	(DRC)	are	labeled	as	DRC	in	the	
Source	column.	Six	common	CTs	of	the	Pasteur	Institute	CRISPOL	database	(labeled	as	reference)	are	also	shown.	These	CTs	are	from	
strains	of	serotype	Typhimurium	02–1800	(CT34,	DT120),	02–5270	(CT21,	DT104),	LT2	(CT41,	DT4),	02–2561	(CT46,	DT12),	02–1749	
(CT7, DT14) or its monophasic variant of antigenic formula 1,4,[5],12:i:-,	07–1777	(CT1,	DT193).	For	each	distinct	CT,	the	numbers	of	
corresponding isolates, their sequence types (STs), and their antimicrobial drug susceptibility testing (AST) data are indicated. For the 
ST and AST columns, the numbers in parentheses refer to the number (>2) of tested isolates with such result. AST data are shown only 
for	DRC	isolates.	The	resistance	types	were	as	follows:	R1,	ASKTNGSulTmpC;	R2,	ASKTNGSulTmpCTe;	R3,	AC;	R4,	ASSulTmp;	R5,	
ASSulTmpC;	R6,	ASSulTmpCNal;	R7,	ASSulTmpCTe;	R8,	ASulTmpC;	R9,	SSulTmpC;	R10,	ACroCazSKTNGSulTmpCTeAzi;	and	R11,	
ACroSKTNGSulTmpCTeNaAzi.	Abbreviations	used	in	the	descriptions	of	resistance	types	are	as	follows:	A,	amoxicillin;	Cro,	ceftriaxone;	
Caz;	ceftazidime;	S,	streptomycin;	K,	kanamycin;	T,	tobramycin;	N,	netilmicin;	G,	gentamicin;	Sul,	sulfamethoxazole;	Tmp,	trimethoprim;	
C,	chloramphenicol;	Te,	tetracycline;	Nal,	nalidixic	acid;	Azi,	azithromycin.
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